{
    "clinical_study": {
        "@rank": "117535", 
        "arm_group": [
            {
                "arm_group_label": "RD047-023", 
                "arm_group_type": "Experimental", 
                "description": "RD-047-023"
            }, 
            {
                "arm_group_label": "Predicate Device", 
                "arm_group_type": "Active Comparator", 
                "description": "legally marketed predicate device"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether a developmental formulation is\n      substantially equivalent to the predicate device in the treatment of hypertrophic and keloid\n      scars."
        }, 
        "brief_title": "A Substantial Equivalence Study of RD04723 and Predicate Device", 
        "condition": [
            "Hypertrophic Scar", 
            "Keloid Scar"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertrophy", 
                "Keloid", 
                "Cicatrix, Hypertrophic", 
                "Cicatrix"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide informed consent and release health information\n\n          -  Ability to follow study instructions and study requirements\n\n          -  Have a hypertrophic or keloid scar accessible for treatment and evaluation\n\n          -  Negative pregnancy test for women of childbearing potential\n\n          -  Agreement to use effective birth control method for study duration\n\n        Exclusion Criteria:\n\n          -  History of allergy or sensitivity to components\n\n          -  History of diabetes\n\n          -  History of collagen vascular disorders\n\n          -  Anticipated need for surgery or hospitalization during the study\n\n          -  Pregnant, nursing, or planning a pregnancy during the study\n\n          -  Current enrollment in an investigational drug or device study or participation in\n             such a study within the last 30 days prior to Baseline (Day 0)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736969", 
            "org_study_id": "MSM-RD-023"
        }, 
        "intervention": [
            {
                "arm_group_label": "RD047-023", 
                "description": "Experimental hydrogel", 
                "intervention_name": "RD047-023", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Predicate Device", 
                "intervention_name": "Predicate Device", 
                "intervention_type": "Device", 
                "other_name": "Kelo-Cote"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 30, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78759"
                }, 
                "name": "DermResearch Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Microcyn Scar Management HydroGel, K103163 vs. Kelo-cote\u00ae Scar Gel for the Management of Hypertrophic or Keloid Scars", 
        "overall_official": {
            "affiliation": "DermResearch Inc.", 
            "last_name": "Janet C DuBois, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Vascularity, height/thickness, pliability, and pigmentation. Scoring from zero to thirteen.", 
            "measure": "Comparison between groups in Vancouver Scar Scale total score from Baseline to Day 112 (or early termination)", 
            "safety_issue": "No", 
            "time_frame": "4 weeks, 8 weeks, 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736969"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patient assessment of pain and itch. Scoring from 0-3.", 
                "measure": "Pain and itch", 
                "safety_issue": "No", 
                "time_frame": "4 weeks, 8 weeks, 12 weeks"
            }, 
            {
                "description": "Number of subjects with related adverse events", 
                "measure": "Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Weeks: 2, 4, 8, 12 and early termination"
            }, 
            {
                "description": "Patient assessment (satisfaction) with scar treatment. Stated as: \"very good, good, moderate or unsatisfactory\".", 
                "measure": "Treatment satisfaction", 
                "safety_issue": "No", 
                "time_frame": "8 weeks, 12 weeks"
            }
        ], 
        "source": "Oculus Innovative Sciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oculus Innovative Sciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}